Pfizer
PFE
29.47
+0.03
+0.09%
Pfizer
US · PFE
#133 by market cap
Listed 1970
29.47
+0.03
+0.09%
Live - 5344 symbols - heartbeat 494s ago
· 2026-10-16 10:40
Analyst consensus 19 analysts
Buy
Avg price target 30.25 +2.7%
Price target rangecurrent 29.47
Low25.00
Avg30.25
High36.00
Buy 42%
Hold 53%
Sell 5%
Recent ratings (25)
| Date | Firm | Analyst | Rating | Target |
|---|---|---|---|---|
| 2026-10-09 | BofA Securities | -- | Hold | 29.00 |
| 2026-10-09 | J.P. Morgan | -- | Hold | 30.00 |
| 2026-10-08 | Cantor Fitzgerald | -- | Hold | 28.00 |
| 2026-10-08 | DBS | -- | Buy | 35.00 |
| 2026-10-08 | Jefferies | -- | Buy | 36.00 |
| 2026-10-07 | Scotiabank | -- | Buy | 33.00 |
| 2026-10-07 | Morgan Stanley | -- | Hold | 28.00 |
| 2026-10-06 | Scotiabank | -- | Buy | 33.00 |
| 2026-10-02 | Scotiabank | -- | Buy | 30.00 |
| 2026-10-02 | Jefferies | -- | Buy | 35.00 |
| 2026-09-22 | Bernstein | -- | Hold | 29.00 |
| 2026-09-21 | Wells Fargo | -- | Hold | 28.00 |
| 2026-09-10 | HSBC | -- | Hold | 30.00 |
| 2026-08-24 | Scotiabank | -- | Buy | 30.00 |
| 2026-08-20 | Bernstein | -- | Hold | 29.00 |
| 2026-08-17 | BMO Capital | -- | Buy | 30.00 |
| 2026-08-13 | Barclays | -- | Sell | 25.00 |
| 2026-08-11 | TD Cowen | -- | Hold | -- |
| 2026-08-07 | CMBI | -- | Buy | 35.75 |
| 2026-08-06 | DZ BANK AG | -- | Buy | -- |
| 2026-08-06 | Guggenheim | -- | Buy | 31.00 |
| 2026-08-05 | Wells Fargo | -- | Hold | 28.00 |
| 2026-08-05 | Argus Research | -- | Buy | -- |
| 2026-08-05 | Scotiabank | -- | Buy | 30.00 |
| 2026-08-05 | Jefferies | -- | Buy | 34.00 |
Quant vs Street three independent views, side by side
Momentum strategy signal
Hold
Analyst consensus
Buy
Signals diverge - worth digging into why.
Not investment advice. The factor grade ranks this stock on fundamentals against StockVane's covered universe; the momentum strategy signal is a rules-based backtest, not a recommendation; analyst consensus reflects sell-side coverage. The three use different methods and can reasonably disagree.
Price target trend monthly average, last 3 years
✦ Quant Analyst Revision Trend how this is computed
Mixed
2 2
■ Upgrades■ Downgrades
- 2 upgrades vs 2 downgrades among tracked analyst rating changes.
- Most recent: RBC Capital moved from Sell to Hold on 2026-07-10.
Recent rating changes
| Date | Firm | Change | Target |
|---|---|---|---|
| 2026-07-10 | RBC Capital | Sell → Hold | 25.00 |
| 2026-07-06 | HSBC | Buy → Hold | 28.00 |
| 2026-05-05 | Goldman Sachs | Buy → Hold | 26.00 |
| 2026-04-16 | Goldman Sachs | Hold → Buy | 33.00 |
Earnings history price reaction on the day
| Period | Report date | Session | Options expected | Actual move |
|---|---|---|---|---|
| 2026/Q2 | 2026-08-04 | -- | ±2.36% | +1.52% (in line) |
| 2026/Q1 | 2026-05-05 | -- | ±3.58% | +0.57% (in line) |
| 2025/Q4 | 2026-02-03 | -- | ±3.03% | -3.34% (beat) |
| 2025/Q3 | 2025-11-04 | -- | ±3.99% | -1.46% (in line) |
| 2025/Q2 | 2025-08-05 | -- | ±5.03% | +5.18% (beat) |
| 2025/Q1 | 2025-04-29 | -- | ±4.32% | +3.21% (in line) |
| 2024/Q4 | 2025-02-04 | -- | ±4.58% | -1.26% (in line) |
| 2024/Q3 | 2024-10-29 | -- | ±4.08% | -1.39% (in line) |
| 2024/Q2 | 2024-07-30 | -- | ±5.14% | +2.18% (in line) |
| 2024/Q1 | 2024-05-01 | -- | ±4.83% | +6.09% (beat) |
| 2023/Q4 | 2024-01-30 | -- | ±4.22% | -1.67% (in line) |
| 2023/Q3 | 2023-10-31 | -- | ±4.27% | +0.03% (in line) |
"Options expected" is the pre-earnings options market's implied move (a straddle-style estimate), shown next to what actually happened.
Quote time 2026-10-16 10:40:10 · For reference only, not investment advice and not tailored to your situation.
Pfizer discussion 0 comments